title: [Control of the systolic blood pressure and related factors in patients with high cardiovascular risk].
abstract: OBJECTIVE
  To know in a good therapeutic compliance population with high cardiovascular risk (HCR), the systolic blood pressure (SBP) control-rate and the factors that could influence.
  
  
  METHODS
  A cross-sectional observational study was carried out in a HCR hypertensive population in Cáceres (Spain). A survey of different laboratory tests, SBP in first and last visits.
  
  
  RESULTS
  Among 388 HCR hypertensive patients, 199 (51.4%) patients with antihypertensive treatment adherence was selected. The average age was of 63 +/- 11 years, 109 (54.1%) males, 61 (30.7%) diabetes mellitus (DM) ones, the 10 years global cardiovascular risk was 22.25 +/- 8.9%, average follow-up was 16.5 +/- 8 months, means SBP was 158 +/- 22 mm Hg. 59.5% with combined treatment, generally diurets with another antihypertensive one. SBP less 140 mm Hg was observe in 23.9% and, only 13.5% less than 130 mm Hg in DM patients. SBP control was more common in less than five years hypertension diagnosis (with respect to those of more time evolution (33.8% vs 15.7%: p < 0.01). as well as, in those with beat pressure (BP) less of 60 mmHg (73.3% versus 26.7%; p < 0.0005). In multivariable analysis also influences negatively in the SBP control: upper 5 years hypertension diagnosis, OR 1.92 (1.08-3.4; p < 0.05) and, a greater BP of 60 mmHg, OR 30.3 (10.6-87: p < 0.0001).
  
  
  CONCLUSIONS
  SBP control is difficult to obtain in a population of HCR and good therapeutic compliance, but more still in DM patients. A time of more 5 years evolution of the hypertension and, BP upper of 60 mm HG, have a negative influences in the SBP control.
authors.affiliation: Servicio de Medicina Interna, Hospital San Pedro de Alcántara, Cáceres. juanf.sanchezm@ses.juntaex.es
authors.forename: J F
authors.initials: JF
authors.lastname: Sánchez Muñoz-Torrero
authors.forename: L
authors.initials: L
authors.lastname: Crespo Rincón
authors.forename: M
authors.initials: M
authors.lastname: Chiquero Palomo
authors.forename: C
authors.initials: C
authors.lastname: Doncel Rancel
authors.forename: A
authors.initials: A
authors.lastname: Bacaicoa López de Sabando
authors.forename: A
authors.initials: A
authors.lastname: Costo Campoamor
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000145:classification / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D015331:Cohort Studies; D015897:Comorbidity; D003430:Cross-Sectional Studies; D048909:Diabetes Complications / Q000453:epidemiology; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000453:epidemiology; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012042:Registries; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D013599:Systole / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents